Scilex Announces Voluntary $13.2M Early Payment On Oramed Note, Full Retirement Set For March 2025
Scilex Announces Voluntary $13.2M Early Payment On Oramed Note, Full Retirement Set For March 2025
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing the treatments for obesity, neurodegenerative, cardiometabolic disease (following formation of its proposed joint venture with IPMC Company), and non-opioid pain management products for acute and chronic pain, today announced that it has voluntarily made an early installment payment in the aggregate amount of $13.2 million under its senior secured promissory note (the "Oramed Note") issued to Oramed Pharmaceuticals Inc. (NASDAQ:ORMP, "Oramed"))) in September 2023. Subsequent to this early installment payment, the remaining principal balance under the Oramed Note will be payable in one final payment on March 21, 2025, and the Oramed Note will be retired in its entirety.
Scilex控股公司（纳斯达克：SCLX，"Scilex"或"公司"），是一家创新的营收产生公司，专注于收购、开发和商业化肥胖、神经退行性、心脏代谢疾病（在与IPMC公司的拟议合资企业成立后）以及急性和慢性疼痛的非阿片类疼痛管理产品的治疗。今天宣布其已自愿提前支付了1320万美金的部分款项，支付对象为2023年9月向Oramed制药公司（纳斯达克：ORMP，"Oramed"）发行的高级担保 promissory note（"Oramed Note"）。在这笔提前支付后，Oramed Note 的剩余本金将在2025年3月21日支付一次性最终付款，Oramed Note 将被全部注销。